Is the Use of Metoprolol Effective in Infusion, in Critical State of Patients with COVID-19?

  • Guillermo David Barros Bohórquez
  • Helmer Jair Barrios Loaiza
  • Steven Rojas Guerrero
  • Leonardo José Mier Martínez
  • Vanessa Carrillo Redondo
  • Mildred Ximena Torrente Bustamante
  • Andrés Felipe Salas Ramírez
  • Melissa Julieth Aguas Cantillo
Keywords: COVID-19, metoprolol, respiratory failure, immunity

Abstract

Acute respiratory distress syndrome is a common disease with high morbidity and mortality. Recently, it has gained relevance due to the pandemic generated by the SARS-CoV-2 infection, in which a large number of patients have required mechanical ventilation and management of the secondary syndrome. COVID-19 has caused more than 540,000 deaths throughout the world as the pandemic continues affecting millions of patients worldwide (Clemente-Moragón et al., 2021), with a clinical presentation ranging from isolated thrombosis to acute respiratory distress syndrome (ARDS) requiring respiratory support, in which infiltration is involving alveolar by activated neutrophils. The beta-blocker metoprolol has been shown to improve inflammation exacerbated in the setting of myocardial infarction (Middleton et al., 2020).
Published
2021-12-17
Section
Articles